
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has experienced significant stock appreciation of nearly 90% over the past month, driven by increased confidence in its multi-cancer early detection technology following positive data readouts from the PATHFINDER 2 study. The company's Total Addressable Market (TAM) analysis indicates a substantial opportunity in the US and UK, projected to reach approximately $3.7 billion by 2026, growing to about $4.0 billion by 2035. Furthermore, GRAIL has strategically established partnerships to enhance its market access, bolstered by over $400 million in pending funds that strengthen its balance sheet, suggesting a robust growth trajectory despite some regulatory uncertainties.
Bears say
GRAIL Inc. has faced substantial net losses since its inception and is projected to continue incurring such losses due to ongoing studies and the necessity of regulatory approvals. The company is operating under significant risks, including potential delays in reimbursement pathways, adoption challenges for its novel multi-cancer early detection test, and competitive pressures from established diagnostics firms. Additionally, the anticipated higher selling, general, and administrative (SG&A) expenses, combined with potential financing issues, may hinder GRAIL’s efforts to successfully commercialize its products and expand its market presence.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares